InnoSer offers new in vivo imaging capabilities

InnoSer offers new in vivo imaging capabilities

InnoSer is acquiring a variety of preclinical imaging modalities for its Diepenbeek facility to offer its customers a comprehensive assessment of their models and compounds. Non-invasive and high-throughput kinetic assays with real-time readouts will improve screening...
InnoSer welcomes Edith Simar as its new Business Development Manager

InnoSer welcomes Edith Simar as its new Business Development Manager

Starting from September 2020, Edith Simar joined the InnoSer team as a business development manager. Thanks to her earlier work and connections in Belgium, France, and Luxembourg Edith will especially strengthen InnoSer’s relationships with (prospective) French...
Let’s reconsider your research – InnoSer contract breeding services

Let’s reconsider your research – InnoSer contract breeding services

COVID-19 restrictions brought extra challenges to breeding and maintaining colonies within academic facilities. If you are looking for a service provider resilient to today’s vulnerable environment, InnoSer is here to support you. Let’s put your research back on track...
InnoSer participates in the AACR annual meeting 2020

InnoSer participates in the AACR annual meeting 2020

InnoSer is proud to announce its participation in the annual meeting of the American Association for Cancer Research. As committed contributors to the preclinical oncology field, we look forward to interacting with the community throughout the event. We make this...
InnoSer joins the Eurostars funded project ‘LEMONAID’

InnoSer joins the Eurostars funded project ‘LEMONAID’

LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...